Pepgen

PepGen is a biotechnology company specializing in the development of next-generation oligonucleotide therapies for neuromuscular and neurodegenerative diseases. They leverage their proprietary Enhanced Delivery Oligonucleotide (EDO) platform to create treatments that significantly improve cellular uptake and therapeutic efficacy. Founded in 2018, PepGen has made notable advancements in preclinical studies, particularly for Duchenne muscular dystrophy and myotonic dystrophy type 1. Their revenue model primarily involves research funding, partnerships, and potential future commercialization of their therapies.

Recent Posts by Pepgen

1-20 of 24